These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34337512)

  • 41. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.
    Kamat AM; Dickstein RJ; Messetti F; Anderson R; Pretzsch SM; Gonzalez GN; Katz RL; Khanna A; Zaidi T; Wu X; Grossman HB; Dinney CP
    J Urol; 2012 Mar; 187(3):862-7. PubMed ID: 22245325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
    Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
    Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.
    Ferro M; Tătaru OS; Musi G; Lucarelli G; Abu Farhan AR; Cantiello F; Damiano R; Hurle R; Contieri R; Busetto GM; Carrieri G; Cormio L; Del Giudice F; Sciarra A; Perdonà S; Borghesi M; Terrone C; La Civita E; Bove P; Autorino R; Muto M; Crisan N; Marchioni M; Schips L; Soria F; Terracciano D; Papalia R; Crocetto F; Barone B; Russo GI; Luzzago S; Ludovico GM; Vartolomei MD; Mistretta FA; Mirone V; de Cobelli O
    Diagnostics (Basel); 2022 Feb; 12(3):. PubMed ID: 35328139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
    Kudo T; Iwasa N; Maeda S; Mitarai S
    Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation.
    Lin PT; Hsieh ML; Su SH; Chang YH; Huang LK; Chu YC; Kan HC; Lin PH; Yu KJ; Chuang CK; Wu CT; Pang ST; Shao IH
    Cancer Manag Res; 2022; 14():3121-3130. PubMed ID: 36386555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
    Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
    Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38355375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
    Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
    Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure.
    Shantharam G; Amin A; Pereira J; Kott O; Mueller-Leonhard C; Mega A; Golijanin D; Gershman B
    Curr Urol; 2021 Mar; 15(1):33-38. PubMed ID: 34084119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
    Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
    Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
    Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.